N Engl J Med. 1997;337:1118 23. 318. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673 82. 319. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716 22. 320. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction:Anglo-Scan- dinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525 30. 321. Bonnefoy E, Godon P, Kirkorian G, et al. Significance of serum troponin I elevation in patients with acute aortic dissection of the ascending aorta. Acta Cardiol. 2005;60:165 70. 322. Langer A, Goodman SG, Topol EJ, et al; LATE Study Investigators. Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. J Am Coll Cardiol. 1996;27:1327 32. 323. Terkelsen CJ, Lassen JF, N rgaard BL, et al. Are we underestimating the full potential of early thrombolytic treatment in patients with acute myocardial infarction? Heart. 2003;89:483 4. 324. The GUSTO Angiographic Investigators. The effects of tissue plasmino- gen activator, streptokinase, or both on coronary-artery patency, ventric- ular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615 22. Erratum in: N Engl J Med. 1994;330:516. 325. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation. 2001;103:2862 6. 326. Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol. 1992;19:885 91. 327. Deleted in press. 328. Cannon CP, McCabe CH, Gibson CM, et al. 